Inhibition of the IL-17 pathway with secukinumab for the treatment of irAEs was associated with tumor progression in a single patient report, but other reports indicated successful irAE treatment without concurrent tumor growth (81, 84). The gene discussed is IL17A; the disease is neoplasm.